Alkem Laboratories Ltd is one of India’s leading pharmaceutical companies. Established in 1973 and headquartered in Mumbai, Alkem has built a strong presence in both domestic and international markets.
Mumbai-based Alkem Laboratories has announced the launch of Kojiglo serum in India for managing facial hyperpigmentation. Alkem is the first Indian company to introduce a liposomal serum with Duo-Lipo technology. The serum is suitable for all skin types.
This innovative formulation combines cutting-edge ingredients such as liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha-arbutin, and niacinamide, making it the first of its kind in India to have a Duo-Lipo technology.
This advanced serum encapsulates the active ingredients in a liposomal form to enhance penetration in the skin and deliver targeted action. This formulation ensures effective results while reducing the risk of skin sensitivity and irritation.
The active pharmaceutical ingredients are carefully sourced to meet global quality standards, offering a high-quality, reliable solution for facial hyperpigmentation. With the introduction of Kojiglo serum, Alkem aims to broaden its portfolio and increase its market share in the skincare segment.
Dr Vikas Gupta, Chief Executive Officer, Alkem, said, “The prevalence of skin hyperpigmentation among the Indian population is quite high, and awareness about managing this condition is gradually increasing. We are pleased to introduce an advanced serum designed to effectively address hyperpigmentation concerns.”
Alkem Laboratories reported an 11% YoY rise in consolidated net profit to ₹689 crore for Q2 FY25, despite a 0.7% dip in revenue to ₹3,414.6 crore. Domestic sales grew 5.7% to ₹2,461 crore, while international sales fell 12.9% to ₹918.1 crore. EBITDA remained stable at ₹753 crore, with margins improving to 22%. R&D expenses rose to ₹146.5 crore, accounting for 4.3% of revenue.
At 9:45 AM on February 5, 2025, Alkem Laboratories Ltd. shares traded at ₹5,105 on the NSE.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Feb 5, 2025, 2:12 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
